about
Human chromosome 7: DNA sequence and biologyAutomated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterationsGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesThe homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesisCEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.TP53 mutation and survival in chronic lymphocytic leukemia.RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.Genomic Classification and Prognosis in Acute Myeloid Leukemia.Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemiaReceptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemiamRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapiesAcute Myeloid LeukemiaInactivating CUX1 mutations promote tumorigenesisThe European Hematology Association Roadmap for European Hematology Research: a consensus documentMDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisQuantitative analysis of DNA methylation in chronic lymphocytic leukemia patients.Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupFludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.Precision oncology for acute myeloid leukemia using a knowledge bank approach.Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells.Quantitative DNA methylation predicts survival in adult acute myeloid leukemia.Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemiaInteractions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells.
P50
Q24596489-74D3D5C8-BD0B-4386-88EC-58FF339C0F92Q24598248-B53CD6E2-1148-4CCC-A93C-283D4350274FQ24616084-2B3E9C2B-81AF-4195-B31F-D832CACFD89BQ24683173-0A86386B-0425-49D2-A420-26263F745D66Q27824809-134D7F6B-9C08-473A-9D0A-BD4800E248B6Q27824843-7F832F43-D2CB-486F-A61B-C0C5D9B9FC0EQ27851430-D8FABBC9-8443-460B-851C-4A37B1D97ADAQ27851444-88CB661B-F85B-4914-87C3-9F0A5BAA78F0Q27851460-1E8DF05B-0E62-4D96-92B8-5CCA4FB7DB53Q27851464-D7E764C7-A647-4107-8FFF-E73AF75E3708Q27851577-38911F1C-9349-4A23-8AC0-4F275F26F544Q27851623-5719787E-BCED-4E41-AAAD-FF5CF3D077A4Q27851736-869B8716-7D63-4E3D-BCCD-F12FF316DFFFQ27852247-AD561F58-B916-4C1E-9BE7-F18838F1851EQ27853002-2F93AA62-DF1A-4E33-8457-430CEC39B83CQ27853387-B9D155BF-9C31-4E0F-B0ED-E52046FBC0C7Q27853389-99D37ADC-26DC-4100-8A8C-B4BE8B7F8156Q28178372-2FF6AFB7-54F4-4B77-9512-BD68116C7FC0Q28201442-0D0AD8BB-AC61-4804-AC80-7DE3B912886CQ28236215-668664CF-3406-43A3-A264-4877AB0C1F52Q28267442-748FC343-6594-4F98-9462-A8F524F6181CQ28303563-1D0A4F40-8F8A-47C4-A75A-70DD8462721EQ28830861-DE8DC41F-D952-4B63-BC57-40598EE0E2E9Q30840070-EBBE7657-D35F-49EC-A2FE-939688FC713FQ31076515-54317880-46D4-4FFE-A9AD-AAAC73DF6320Q31114679-CEE487AF-4C83-4C4D-9A1F-01FCDC5FAB79Q31163049-7F5BB5FE-FFEE-4F96-80B3-DB7204CA36EDQ33368885-1FEDBE2B-EA1E-4AC3-A987-F5E4E90824F1Q33385371-E14E78FA-FFF1-4E71-BB41-56517B089D4CQ33396737-411BBF4F-848D-459F-988B-C5C52C88415CQ33402713-6B402536-CB3E-4C2F-9F00-E28F23B530DDQ33409020-DBC125B0-DB42-4BE6-95DF-6D08DF9A33EBQ33417548-D55F903F-94A8-483A-9050-6AF4611A2AF0Q33432481-D3A5029E-980E-4DE0-B958-5AC38EAF9E08Q33458896-DB934C6D-D711-4B98-BBE1-B35B3B9F5917Q33494799-4FF22553-A47A-4016-8C31-C284BF771151Q33515724-6B9BAA39-95FD-465F-8B1B-87F5B7495DBAQ33587644-4C1D074B-36FD-4197-BEB8-9CBF08ECB098Q33695990-26A61F38-9EAD-42ED-96B2-CC4C19E023D4Q33917885-E17585C7-B1F4-4822-8F7A-F222E764D176
P50
name
Hartmut Döhner
@ast
Hartmut Döhner
@en
Hartmut Döhner
@nl
type
label
Hartmut Döhner
@ast
Hartmut Döhner
@en
Hartmut Döhner
@nl
prefLabel
Hartmut Döhner
@ast
Hartmut Döhner
@en
Hartmut Döhner
@nl